AbbVie Inc. Stock
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 2.510% | 2.321% | -2.783% | 14.748% | 5.739% | 59.136% | 113.982% |
| Pfizer Inc. | 1.400% | -0.751% | 9.877% | -25.891% | 1.226% | -17.127% | -25.294% |
| Elanco Animal Health Inc. | 0.760% | 4.935% | 31.803% | 113.202% | 20.163% | -44.723% | - |
| Biogen Inc. | 2.070% | 3.184% | 2.979% | -25.234% | -12.044% | -5.210% | 5.333% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on the provided financial statements, AbbVie Inc., a prominent company in the pharmaceutical industry, appears to be maintaining a strong financial position. The company has demonstrated consistent growth in revenues and net income over the years. However, there are also challenges in certain aspects that could impact the company's financial health.
Revenue growth: From 2020 to 2022, AbbVie's total revenues increased from €45.8 billion to $58.0 billion, signifying a healthy growth rate. This suggests a strong demand for their products and services in the pharmaceuticals industry.
Net income growth: Net income has shown a steady increase. In 2020, the net income stood at €4.6 billion, which rose to €11.5 billion in 2021 and further increased to $11.8 billion in 2022.
Comments
News
3 Dividend Stocks to Double Up on Right Now
Sometimes, misperceptions can work in investors' favor. When others think the outlook for a stock isn't so great, you can win big if that view is overly pessimistic.
Several stocks that pay
Forget Nvidia, Buy This Magnificent Healthcare Stock Instead
Nvidia (NASDAQ: NVDA) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Relax, do what you enjoy, and rake in money. That probably sounds like a great life for most people. Making it a reality isn't easy, but it's possible.
The key is to generate passive income. You'll